🔗 Permalink

Inventor profile of:

Ralph R. Weichselbaum

City:

Chicago, Illinois

Country:

United States

Published Applications:

Last publication date:

2026-02-05

Top Assignees for applications by Ralph R. Weichselbaum

The entities that hold a legal rights for patent applications filed by inventor Weichselbaum Ralph R.:

THE UNIVERSITY OF CHICAGO 20 Chicago, IL United States
Dana-Farber Cancer Institute 7 Boston, MA United States
ARCH DEVELOPMENT CORPORATION 7 Chicago, IL United States
Dana-Farber-Cancer Institute, Inc. 5 Boston, MA United States
U A B RESEARCH FOUNDATION 1 Birmingham, AL United States
UNIVERSITY OF CHICAGO 1 CHICAGO, IL United States
UAB Research Foundation 1 Birmingham, AL United States

Recent patent applications by Weichselbaum Ralph R.

Ralph R. Weichselbaum from Chicago, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-02-05

US20260035696A1

Chemistry; metallurgy

COMBINATION TREATMENT FOR CANCER

#2 | 2024-01-04

US20240000741A1

Human necessities

ALL-TRANS RETINOIC ACID ENHANCES RADIOTHERAPY AND OVERCOMES IMMUNE SUPPRESSION FOR CANCER THERAPY

#3 | 2022-02-17

US20220047892A1

Human necessities

System and method for multi-site radiotherapy

#4 | 2022-01-27

US20220025004A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS RELATED TO SITE-SPECIFIC IDENTIFICATION OF RNA MODIFICATIONS

#5 | 2021-04-22

US20210115519A1

Chemistry; metallurgy

METHODS AND KITS FOR DIAGNOSIS AND TRIAGE OF PATIENTS WITH COLORECTAL LIVER METASTASES

#6 | 2018-09-13

US20180256678A1

Human necessities

Anti-tumor therapy

#7 | 2017-09-21

US20170268001A1

Chemistry; metallurgy

RNAS WITH TUMOR RADIO/CHEMO-SENSITIZING AND IMMUNOMODULATORY PROPERTIES AND METHODS OF THEIR PREPARATION AND APPLICATION

#8 | 2016-12-22

US20160369353A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS RELATING TO CANCER THERAPY WITH DNA DAMAGING AGENTS

#9 | 2016-12-22

US20160367627A1

Human necessities

ANTI-TUMOR THERAPY

#10 | 2016-08-04

US20160222387A1

Chemistry; metallurgy

Anti-tumor therapy

#11 | 2015-01-22

US20150024008A1

Human necessities

Methods and Compositions Involving Induced Senescent Cells for Cancer Treatment

#12 | 2014-05-22

US20140142103A1

Human necessities

Methods and compositions for modulating RAD51 and homologous recombination

#13 | 2013-06-27

US20130164811A1

Human necessities

DNA DAMAGING AGENTS IN COMBINATION WITH TYROSINE KINASE INHIBITORS

#14 | 2013-02-14

US20130039890A1

Chemistry; metallurgy

Treatment of tumors with genetically engineered herpes virus

#15 | 2011-11-10

US20110274661A1

Chemistry; metallurgy

Attentuated Herpesvirus Encoding a Mek Pathway Polypeptide

#16 | 2011-04-21

US20110091375A1

Human necessities

USE OF THE COMBINATION COMPRISING TEMOZOLOMIDE AND TNF-ALPHA FOR TREATING GLIOBLASTOMA

#17 | 2011-03-03

US20110053240A1

Human necessities

DNA DAMAGING AGENTS IN COMBINATION WITH TYROSINE KINASE INHIBITORS

#18 | 2011-02-24

US20110046211A1

Human necessities

COMBINATION THERAPY OF HEDGEHOG INHIBITORS, RADIATION AND CHEMOTHERAPEUTIC AGENTS

#19 | 2011-01-06

US20110002890A1

Chemistry; metallurgy

Treatment of tumors with genetically engineered herpes virus

#20 | 2010-09-30

US20100248371A1

Human necessities

Methods and compositions for modulating RAD51 and homologous recombination

#21 | 2009-04-09

US20090093429A1

Human necessities

COMBINATION THERAPY FOR TREATING CANCER

#22 | 2008-05-22

US20080118471A1

Human necessities

Constitutive gene expression in conjunction with ionizing radiation

#23 | 2008-01-17

US20080014175A1

Human necessities

Methods and Compositions for Viral Enhancement of Cell Killing

#24 | 2007-12-06

US20070281040A1

Human necessities

COMBINATION THERAPY OF HEDGEHOG INHIBITORS, RADIATION AND CHEMOTHERAPEUTIC AGENTS

#25 | 2007-09-13

US20070212298A1

Human necessities

USE OF THE COMBINATION COMPRISING TEMOZOLOMIDE AND TNF-ALPHA FOR TREATING GLIOBLASTOMA

#26 | 2007-08-16

US20070190165A1

Human necessities

Tissue-specific basement membrane gels

#27 | 2007-07-24

US10244705

Use of DF3/MUC1 regulated expression in gene therapy

#28 | 2007-05-10

US20070105772A1

Physics

Induction of apoptosis by cellular stress

#29 | 2007-02-15

US20070036748A1

Human necessities

Activation of Egr-1 promoter by DNA damaging chemotherapeutics

#30 | 2006-11-09

US20060251734A1

Human necessities

DNA damaging agents in combination with tyrosine kinase inhibitors

#31 | 2006-10-10

US10125003

Induction of apoptosis by cellular stress

#32 | 2006-07-04

US10375684

DNA damaging agents in combination with tyrosine kinase inhibitors

#33 | 2006-06-01

US20060113482A1

Physics

Image-guided medical intervention apparatus and method

#34 | 2006-05-09

US9730630

Gene transcription and ionizing radiation: methods and compositions

#35 | 2006-03-16

US20060058258A1

Human necessities

Gene transcription and ionizing radiation: methods and compositions

#36 | 2005-07-07

US20050147591A1

Human necessities

Methods and compositions for viral enhancement of cell killing

#37 | 2005-03-03

US20050048491A1

Physics

Methods and kits for use in selecting approaches to treating cancer

#38 | 2005-01-25

US9995475

Genetically engineered herpes virus for the treatment of cardiovascular disease

InventorID:

89098 ⎘